Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMPD1 | P17405 | 3/20 | 0.67 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.53 |
| ▸ | FDPS | P14324 | 5/20 | 0.52 |
| ▸ | S1PR2 | O95136 | 5/20 | 0.49 |
| ▸ | S1PR1 | P21453 | 5/20 | 0.49 |
| ▸ | S1PR3 | Q99500 | 5/20 | 0.49 |
| ▸ | S1PR4 | O95977 | 4/20 | 0.49 |
| ▸ | LAP3 | P28838 | 2/20 | 0.48 |
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.47 |
| ▸ | LPAR1 | Q92633 | 3/20 | 0.47 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3632792 | 1.00 | SMPD1 (0.67) | SMPD1PTPN1FDPSS1PR2S1PR1 | |
| SCHEMBL27486860 | 1.00 | SMPD1 (0.67) | SMPD1PTPN1FDPSS1PR2S1PR1 | |
| SCHEMBL29758198 | 1.00 | SMPD1 (0.67) | SMPD1PTPN1FDPSS1PR2S1PR1 | |
| SCHEMBL3624518 | 1.00 | SMPD1 (0.67) | SMPD1PTPN1FDPSS1PR2S1PR1 | |
| SCHEMBL14368863 | 1.00 | SMPD1 (0.67) | SMPD1PTPN1FDPSS1PR2S1PR1 | |
| SCHEMBL10690779 | 1.00 | SMPD1 (0.67) | SMPD1PTPN1FDPSS1PR2S1PR1 | |
| SCHEMBL28982704 | 0.98 | SMPD1 (0.65) | SMPD1PTPN1FDPSS1PR2S1PR1 | |
| SCHEMBL3629609 | 0.98 | SMPD1 (0.65) | SMPD1PTPN1FDPSS1PR2S1PR1 | |
| SCHEMBL3631672 | 0.98 | SMPD1 (0.65) | SMPD1PTPN1FDPSS1PR2S1PR1 | |
| SCHEMBL4941232 | 0.98 | SMPD1 (0.63) | SMPD1PTPN1FDPSS1PR2S1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1633440-A | Branched-chain lipophilic molecule derivatives and uses thereof | DPHARM LTD (IL) | 2005-06-29 | — | — | CN | claimed |
| EP-1305322-A4 | DERIVATIVES OF BRANCHED-CHAIN LIPOPHILIC MOLECULES AND USES THEREOF | DPHARM LTD (IL) | 2005-04-13 | — | — | EP | claimed |
| JP-2004505898-A | — | — | 2004-02-26 | — | — | JP | claimed |
| US-20030186897-A1 | Derivatives of branched-chain lipophilic molecules and uses thereof | D-PHARM, LTD. (IL) | 2003-10-02 | — | — | US | claimed |
| EP-1305322-A2 | DERIVATIVES OF BRANCHED-CHAIN LIPOPHILIC MOLECULES AND USES THEREOF | D-Pharm Ltd. (IL) | 2003-05-02 | — | — | EP | claimed |
| WO-2002011666-A2 | DERIVATIVES OF BRANCHED-CHAIN LIPOPHILIC MOLECULES AND USES THEREOF | D-PHARM LTD. (IL) | 2002-02-14 | — | — | WO | claimed |
| CN-119258567-A | Radioactive organic waste liquid rectifying device and rectifying method | 中核四川环保工程有限责任公司 | 2025-01-07 | — | — | CN | disclosed |
| US-7687483-B2 | Derivatives of branch-chain lipophilic molecular and uses thereof | D-PHARM LTD. (IL) | 2010-03-30 | — | — | US | disclosed |
| EP-1305322-B1 | DERIVATIVES OF BRANCHED-CHAIN LIPOPHILIC MOLECULES AND USES THEREOF | DPHARM LTD (IL) | 2010-01-13 | — | — | EP | disclosed |
| US-20070135381-A1 | Derivatives of branch-chain lipophilic molecular and uses thereof | D-PHARM LTD. (IL) | 2007-06-14 | — | — | US | disclosed |
| US-7186703-B2 | Derivatives of branched-chain lipophilic molecules and uses thereof | D-PHARM LTD. (IL) | 2007-03-06 | — | — | US | disclosed |
| CN-1633440-A | Branched-chain lipophilic molecule derivatives and uses thereof | DPHARM LTD (IL) | 2005-06-29 | — | — | CN | disclosed |
| EP-1305322-A4 | DERIVATIVES OF BRANCHED-CHAIN LIPOPHILIC MOLECULES AND USES THEREOF | DPHARM LTD (IL) | 2005-04-13 | — | — | EP | disclosed |
| US-20030186897-A1 | Derivatives of branched-chain lipophilic molecules and uses thereof | D-PHARM, LTD. (IL) | 2003-10-02 | — | — | US | disclosed |
| EP-1305322-A2 | DERIVATIVES OF BRANCHED-CHAIN LIPOPHILIC MOLECULES AND USES THEREOF | D-Pharm Ltd. (IL) | 2003-05-02 | — | — | EP | disclosed |
| WO-2002011666-A2 | DERIVATIVES OF BRANCHED-CHAIN LIPOPHILIC MOLECULES AND USES THEREOF | D-PHARM LTD. (IL) | 2002-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135381-A1 | Derivatives of branch-chain lipophilic molecular and uses thereof | PLIN3, GLS, LIPG | SMPD1 172/4885PTPN1 3868/4885FDPS 624/4885 |
| US-20030186897-A1 | Derivatives of branched-chain lipophilic molecules and uses thereof | PLIN3, PLIN5, SLC27A1 | SMPD1 415/4885PTPN1 3060/4885FDPS 957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.